{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:27:54Z","timestamp":1794472074495,"version":"4.9.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019777","name":"EpicentRx","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019777","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AdAPT-001 is an oncolytic adenovirus (OAV) with a transforming growth factor beta (TGF-\u00df) trap, which neutralizes the immunosuppressive and profibrotic cytokine, TGF-\u00df. The aim or purpose of this phase 1 study was to assess the safety and tolerability and, secondarily, the efficacy of AdAPT-001 after single intratumoral injection (IT) (Part 1) and multidose IT injection (Part 2) in patients with superficially accessible, advanced refractory solid tumors. Part 1 enrolled 9 patients with a 3\u2009+\u20093 single dose-escalation safety run-in involving 2.5\u2009\u00d7\u200910<jats:sup>11<\/jats:sup>, 5.0\u2009\u00d7\u200910<jats:sup>11<\/jats:sup>, 1.0\u2009\u00d7\u200910<jats:sup>12<\/jats:sup> viral particles (vps). No dose-limiting toxicities or treatment-related serious adverse events (SAEs) were seen. In Part 2, a dose-expansion phase, 19 patients received AdAPT-001 at 1.0\u2009\u00d7\u200910<jats:sup>12<\/jats:sup>\u2009vps until disease progression according to Response Evaluation Criteria in Solid Tumors or RECIST 1.1. The overall responses to treatment included confirmed partial responses (3), durable stable disease\u2009\u2265\u20096 months (5), and progressive disease (13). AdAPT-001 is well tolerated. Evidence of an anti-tumor effect was seen in both injected and uninjected lesions. The recommended Phase 2 dose was 1.0\u2009\u00d7\u200910<jats:sup>12<\/jats:sup>\u2009vp administered by intratumoral injection once every 2 weeks. Combination of AdAPT-001 with a checkpoint inhibition is enrolling.<\/jats:p>","DOI":"10.1038\/s41417-023-00720-0","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T06:01:46Z","timestamp":1703484106000},"page":"517-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors"],"prefix":"10.1038","volume":"31","author":[{"given":"Anthony P.","family":"Conley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bessudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Gastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Caroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-6329","authenticated-orcid":false,"given":"Bryan","family":"Oronsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Stirn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal A.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Wagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"720_CR1","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3390\/cancers15071947","volume":"15","author":"A Gryciuk","year":"2023","unstructured":"Gryciuk A, Rogalska M, Baran J, Kuryk L, Staniszewska M. Oncolytic adenoviruses armed with co-stimulatory molecules for cancer treatment. Cancers. 2023;15:1947.","journal-title":"Cancers"},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers14194701","volume":"14","author":"B Oronsky","year":"2022","unstructured":"Oronsky B, Gastman B, Conley AP, Reid C, Caroen S, Reid T. Oncolytic adenoviruses: the cold war against cancer finally turns hot. Cancers. 2022;14:4701 https:\/\/doi.org\/10.3390\/cancers14194701.","journal-title":"Cancers"},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","volume":"7","author":"S Gujar","year":"2018","unstructured":"Gujar S, Pol JG, Kroemer G. Heating it up: oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies. Oncoimmunology. 2018;7:e1442169 https:\/\/doi.org\/10.1080\/2162402X.2018.1442169.","journal-title":"Oncoimmunology"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6:19976\u201389. https:\/\/doi.org\/10.18632\/oncotarget.5116.","journal-title":"Oncotarget"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"e1478648","DOI":"10.1080\/2162402X.2018.1478648","volume":"7","author":"C Larson","year":"2018","unstructured":"Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, et al. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology. 2018;7:e1478648.","journal-title":"Oncoimmunology"},{"key":"720_CR6","first-page":"3141","volume":"12","author":"C Larson","year":"2022","unstructured":"Larson C, Oronsky B, Reid T. AdAPT-001, an oncolytic adenovirus armed with a TGF-\u03b2 trap, overcomes in vivo resistance to PD-L1-immunotherapy. Am J Cancer Res. 2022;12:3141\u20137.","journal-title":"Am J Cancer Res."},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14728222.2020.1744568","volume":"24","author":"C Larson","year":"2020","unstructured":"Larson C, Oronsky B, Carter CA, Oronsky A, Knox SJ, Sher D, et al. TGF-beta: a master immune regulator. Expert Opin Ther Targets. 2020;24:427\u201338. https:\/\/doi.org\/10.1080\/14728222.2020.1744568.","journal-title":"Expert Opin Ther Targets"},{"key":"720_CR8","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3390\/cancers15123157","volume":"15","author":"T Dong","year":"2023","unstructured":"Dong T, Shah JR, Phung AT, Larson C, Sanchez AB, Aisagbonhi O, et al. A local and abscopal effect observed with liposomal encapsulation of intratumorally injected oncolytic adenoviral therapy. Cancers. 2023;15:3157 https:\/\/doi.org\/10.3390\/cancers15123157.","journal-title":"Cancers"},{"key":"720_CR9","first-page":"5184","volume":"11","author":"C Larson","year":"2021","unstructured":"Larson C, Oronsky B, Abrouk NE, Oronsky A, Reid TR. Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta. Am J Cancer Res. 2021;11:5184\u20139.","journal-title":"Am J Cancer Res"},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/cgt.2011.41","volume":"18","author":"F Hedjran","year":"2011","unstructured":"Hedjran F, Shantanu K, Tony R. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. Cancer Gene Ther. 2011;18:717\u201323. https:\/\/doi.org\/10.1038\/cgt.2011.41.","journal-title":"Cancer Gene Ther"},{"key":"720_CR11","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1021\/acsbiomaterials.2c00966","volume":"8","author":"CH Huang","year":"2022","unstructured":"Huang CH, Dong T, Phung AT, Shah JR, Larson C, Sanchez AB, et al. Full remission of CAR-deficient tumors by DOTAP-folate liposome encapsulation of adenovirus. ACS Biomater Sci Eng. 2022;8:5199\u2013209. https:\/\/doi.org\/10.1021\/acsbiomaterials.2c00966.","journal-title":"ACS Biomater Sci Eng"},{"key":"720_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/omcr\/omz105","volume":"2019","author":"M Bouvet","year":"2019","unstructured":"Bouvet M, Reid TR, Larson C, Oronsky B, Carter C, Morris JC. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxf Med Case Rep. 2019;2019:461\u20133.","journal-title":"Oxf Med Case Rep"},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ymthe.2004.03.017","volume":"9","author":"TC Liu","year":"2004","unstructured":"Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther. 2004;9:786\u2013803.","journal-title":"Mol Ther."},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/978-1-59745-561-9_35","volume":"542","author":"M Opyrchal","year":"2009","unstructured":"Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol. 2009;542:705\u201317. https:\/\/doi.org\/10.1007\/978-1-59745-561-9_35.","journal-title":"Methods Mol Biol"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"1061394","DOI":"10.3389\/fimmu.2022.1061394","volume":"13","author":"M Yi","year":"2022","unstructured":"Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K. TGF-\u03b2: a novel predictor and target for anti-PD-1\/PD-L1 therapy. Front Immunol. 2022;13:1061394 https:\/\/doi.org\/10.3389\/fimmu.2022.1061394.","journal-title":"Front Immunol"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"e29620","DOI":"10.7759\/cureus.29620","volume":"14","author":"E Nabrinsky","year":"2022","unstructured":"Nabrinsky E, Macklis J, Bitran J. A review of the abscopal effect in the era of immunotherapy. Cureus. 2022;14:e29620 https:\/\/doi.org\/10.7759\/cureus.29620.","journal-title":"Cureus"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00720-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T23:02:38Z","timestamp":1713135758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00720-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1038\/s41417-023-00720-0","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CL, TRR, SC, BO, MS, JW, EB, and AC report employment with and ownership of EpicentRx Inc. stock. No disclosures were reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was carried out with the approval of the Institutional Ethics committee of all participating institutions. The study was conducted in accordance with the ethical principles pronounced in the Declaration of Helsinki (Amendment 64th of the World Medical Association General Assembly, Fortaleza, Brazil, October 2013). This study is registered at the US Government ClinicalTrials.gov database as number NCT04673942. A signed informed consent was obtained from each participant prior to any study procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}